Market OverviewThe Addiction Rehab Facilities Market, valued at USD 16.8 billion in 2023, is anticipated to experience substantial growth, reaching about USD 31.3 billion by 2032. This growth ...

Alkermes is positioned for outperformance due to its conservative cash-heavy balance sheet and high-margin business model.

The price-to-earnings ratio for Alkermes plc (NASDAQ:ALKS) is 9.65. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E ...

Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise ...

Alkermes plc last week announced it had completed the sale of its development and manufacturing facility in Athlone, to Novo ...

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Alkermes (ALKS – Research Report) yesterday and set a price target of $28.00. The company’s shares closed yesterday at $23.86.

Throughout the last three months, 7 analysts have evaluated Alkermes ALKS, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings ...

Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility ...

Alkermes plc ALKS reported adjusted earnings from continuing operations of 44 cents per share for first-quarter 2024, which missed the Zacks Consensus Estimate of 59 cents. The company had ...

Alkermes (NASDAQ:ALKS) just reported results for the first quarter of 2024. Alkermes reported earnings per share of 44 cents. This was below the analyst estimate for EPS of 58 cents. The company ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.